On September 2, CANSINOBIO rose 7.93% in regular trading, trading at HK$31.38/share, with turnover of HK$77.42 million. The rebound followed CLSA's latest research report maintaining an Outperform rating on the company with a target price of HK$49.6, implying approximately 56% upside from current levels.

CLSA raised its net profit forecasts for the company to RMB 121 million, RMB 323 million, and RMB 723 million respectively, citing growth momentum from its recently approved tetanus vaccine. The stock had pulled back over several consecutive trading sessions since August 27 on profit-taking pressure after a strong rally driven by multiple catalysts, including Moderna's positive Phase III mRNA cancer vaccine data, an mRNA tumor vaccine collaboration with deepGeneAI, and the tetanus vaccine NDA approval on August 20.

The company's H1 results showed revenue of RMB 550 million, up 43.81% year-over-year, with net losses narrowing 94.65% to just RMB 720,000. Overseas revenue reached approximately RMB 152 million, achieving significant growth. The company is scheduled to hold an online interim results briefing on September 3.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)